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Abstract
Objective: There are many drug–drug interactions
(D–DI) of which some may cause severe adverse pa-
tient outcomes. Dispensing interacting drug combina-
tions should be avoided when the risks are higher than
the beneﬁts. The objective of this study was to identify
determinants of dispensing undesirable interacting
drug combinations by community pharmacies in the
Netherlands.
Methods: A total of 256 Dutch community pharma-
cies were selected, based on the dispensing of 11
undesirable interacting drug combinations between
January 1st, 2001 and October 31st, 2002. These
pharmacies were sent a questionnaire by the Inspec-
torate for Health Care (IHC) concerning their process
and structure characteristics.
Main outcome measure: The number of times the 11
undesirable interacting drug combinations were dis-
pensed.
Results: Two hundred and forty-six questionnaires
(response rate 96.1%) were completed. Dispensing
determinants were only found for the D–DI between
macrolide antibiotics and digoxin but not for the other
10 D–DIs. Pharmacies using different medication sur-
veillance systems differed in the dispensing of this
interacting drug combination, and pharmacies, which
were part of a health care centre dispensed this inter-
acting drug combination more often.
Conclusion: Medication surveillance in Dutch com-
munity pharmacies seems to be effective. Although
for most D–DIs no determinants were found, process
and structure characteristics may have consequences
for the dispensing of undesirable interacting drug
combinations.
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Statements on the impact of the article on practice
• Process and structure characteristics may inﬂuence
the dispensing of undesirable interacting drug
combinations in community pharmacies but prob-
ably to a minor degree.
• Medication surveillance in Dutch pharmacies seems
to be effective.
Introduction
Drug–drug interactions (D–DIs) are responsible for
many adverse patient outcomes. Different studies
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DOI 10.1007/s11096-006-9061-3suggest that D–DIs may cause up to 3% of all hospital
admissions [1–4]. A D–DI is deﬁned as a pharmaco-
kinetic or pharmacodynamic inﬂuence of drugs on each
other, which may result in desired effects, in reduced
efﬁcacy and effectiveness or in increased toxicity [5].
Although many D–DIs exist, only a small part of these
D–DIs is clinically relevant [6–8]. The potential bene-
ﬁts of drug combinations should be weighed against the
seriousness of the D–DI, taking into account the
availability of alternatives. Only in cases that the risks
associated with the D–DI are higher than the beneﬁts
or if a better alternative is available, the D–DI should
be avoided.
In the Netherlands, one of the tasks of the phar-
macist is to intervene in case of D–DIs, which involve a
high risk for the patient. Hereto, the pharmacist uses
patient characteristics and the medication history. All
prescriptions, which are submitted to the pharmacy,
are screened on potential interactions with the help of
medication surveillance software. These D–DIs are
evaluated by the pharmacist who intervenes if neces-
sary. This task is important but cumbersome, and re-
quires great attention from the pharmacist. The
organisational aspects, such as the tuning of the med-
ication surveillance software and instructions of tech-
nicians, should be managed by the pharmacist in such a
way that in case of D–DIs with a high risk the phar-
macist intervenes. This is important for the prevention
of adverse patient outcomes [9].
The objective of this study was to assess process and
structure characteristics associated with the dispensing
of interacting drug combinations, which carry a high
risk of adverse patient outcomes.
Methods
Setting
The data for this study were retrieved from the Drug
Information Project, a division of the Health Care
Insurance Board. This is a database containing the
reimbursement data from eight health care insurance
companies in the Netherlands. The reimbursement
data from January 1st, 2001 until October 31st, 2002
were analysed. Eleven potential D–DIs, that con-
tained a high risk and could be substituted, because a
good alternative was available, were selected and
counted for each pharmacy in the database. These
undesirable potential D–DIs were mostly interactions
between chronically used drugs which cannot be
interrupted and short-term use of antibiotics or an-
timycotics, and were selected from the Dutch
guidelines for the management of D–DIs (Table 1)
[10, 11]. A D–DI was counted as such, when the
chronically used drug was dispensed both in the
period 150 days preceding and in the period 150 days
after the dispensing of antibiotics or antimycotics for
Table 1 Number of dispensings in the database of the individual drugs involved, the eleven potential D–DIs and the calculated ratio
Drug–drug interaction Number of
dispensings
drug A · 1,000
(range)
Number of
dispensings
drug B · 1,000
(range)
Number of
D–DIs counted
(range)
Average ratio
(range)
a
Drug A Drug B
1 Erythromycin, clarithromycin,
azithromycin, roxithromycin
Digoxin 440.8 (0–2754) 487.0 (0–3064) 3,993 (0–41) 1.39 (0–18.52)
2 Itraconazole Digoxin 88.7 (0–349) 487.0 (0–3064) 245 (0–7) 0.45 (0–21.69)
3 Ciproﬂoxacin Theophylline 105.4 (0–769) 100.9 (0–756) 944 (0–14) 6.39 (0–
534.38)
4 Miconazole oral gel Acenocoumarol,
fenprocoumon
44.6 (0–233) 608.2 (5–3156) 154 (0–3) 0.38 (0–21.30)
5 Erythromycin Carbamazepine 49.7 (0–531) 193.6 (0–871) 35 (0–4) 0.24 (0–40.92)
6 Erythromycin, clarithromycin,
azithromycin
Disopyramide 426.6 (0–2754) 9.4 (0–151) 61 (0–4) –
7 Erythromycin, clarithromycin Pimozide 274.4 (0–2004) 57.4 (0–394) 70 (0–15) 0.46 (0–46.12)
8 Propranolol, oxprenolol, pindolol beta2-mimetics,
inhalation
corticosteroids
250.6 (1–1075) 2,546.9 (27–
10504)
5,127 (0–94) 0.54 (0–12.98)
9 Erythromycin, clarithromycin Cisapride 274.4 (0–2004) 127.5 (0–821) 586 (0–11) 1.16 (0–40.45)
10 Itraconazole, ﬂuconazole,
ketoconazole
Cisapride 199.9 (0–727) 127.5 (0–821) 347 (0–12) 0.95 (0–57.10)
11 Acenocoumarol, fenprocoumon Azapropazon 608.2 (5–3156) 8.4 (0–164) 32 (0–19) –
a Calculated with Formula 1
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123short-term use in the same pharmacy. Pharmacies
with less than 5,000 dispensings in the database were
excluded.
Procedure
For each pharmacy, we calculated the dispensing-ratios
for the eleven potential D–DIs with Formula 1. This
formula was used because the risk of dispensing a D–DI
betweendrugAanddrugBisdependentonthenumber
of times each drug is dispensed. The more drug A or
drugBaredispensed,thehighertheriskthatthesedrugs
are combined on the basis of chance alone. In case the
dispensingofdrugAisindependentfromthedispensing
of drug B and the D–DI is never intervened, the ratio
will on average be one. The number of times this ratio
wasaboveonewascalculated,becausearatioaboveone
might indicate that medication surveillance fails. In this
calculation, there were 342 D–DIs between norﬂoxacin
and theophylline, which were excluded in the analysis
because the guidelines concerning the management of
this D–DI were inconsistent. Two groups of pharmacies
were selected, and the pharmacists were asked in Au-
gust 2003 by the Inspectorate for Health Care (IHC) to
ﬁll in a questionnaire. The ﬁrst group included phar-
macies with ahigh risk of dispensing these D–DIs, while
thesecondgroupconsistedofarandomsamplefromthe
remaining pharmacies. These groups were equal in size.
The selection criteria are described in Fig. 1. The
selection criterion for receiving a questionnaire (‡4
times a ratio >1) was chosen on pragmatic reasons to
have enough power for statistical analysis with man-
ageable numbers. A concept questionnaire was com-
posed on basis of a literature search and interviews with
experts [9]. The questions concerned process and
structure characteristics of several quality aspects and
those questions were selected that could discriminate
between high and low quality pharmacies. Mostly
questions with objective answers were included, for
exampleaboutwritteninstructionsfortechnicians,ﬁling
of data, tuning of the software (which signals were
shown and which not) and personnel. The concept
questionnaire was tested in three pharmacies and some
questionswereamendedonthebasisoftheircomments.
The ﬁnal questionnaire contained 183 questions, di-
vided into 12 subjects (Table 2). The questionnaire was
accessible via the Internet. Pharmacies who had no ac-
cess to the Internet received the questionnaire by post.
Pharmacies who failed to ﬁll in the questionnaire re-
ceived reminders at regular intervals. A sample from
both groups was visited by the IHC (Fig. 1). Also here,
the selection criterion (‡5 times a ratio >1) was chosen
to have enough power with manageable numbers.
Thirty-seven questions from the questionnaire were
selected and during the visits these questions were ver-
iﬁed. The pharmacies were informed in advance that a
selection of the pharmacies would be visited. The se-
lectedpharmacies wereacquaintedaftercompletingthe
questionnaire. The visiting inspectors were blinded to
the number of interacting drug combinations.
Formula 1:
Ratio 1 ¼
ki;ab/Ni
ki;a/Ni   ki;b=Ni
Formula 2:
Ratio2 ¼
ki;ab
Ni  
P
i ki;ab/Ntot
ki;a
Ni  
P
i ki;a/Ntot
 
ki;b
Ni  
P
ki;b/Ntot
where
• ki,ab: number of dispensings of interacting drug
combination AB in pharmacy i;
• ki,a: number of dispensings of drug A in pharmacy i;
• ki,b: number of dispensings of drug B in pharmacy i;
• Ni: total number of dispensed drugs known in the
database in pharmacy i;
• Ntot: total number of dispensed drugs known in the
database in all pharmacies
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Fig. 1 The selection of the
pharmacies receiving a
questionnaire and IHC visit
Pharm World Sci (2007) 29:51–57 53
123Statistical analysis
For each pharmacy, dispensing-ratios for the D–DIs,
comparable to the standardised mortality ratio, were
calculated using Formula 2. With this formula, we
standardise for the total number of dispensings per
pharmacy in the database. In case all pharmacies dis-
pense the D–DIs in equal numbers, the ratio will be
one for all pharmacies, and therefore the ratios have a
better comparability. Pharmacies which have only a
small number of dispensings in the database, will have
extremely high numbers in case they dispense one or a
small number of D–DIs. Therefore, the results were
equalized with Bayesian statistics to prevent extreme
ups and downs due to low numbers of dispensings [12].
The pharmacies were divided into two sets. One set
was used for the analyses and contained two-third of
the pharmacies, the other set was used for the valida-
tion of the results obtained in the analyses. In the
univariate analysis, correlations were searched be-
tween the answers in the questionnaire and these ra-
tios. Correlations are only given if in both sets a
correlation was found (p < 0.01). In the multivariate
analysis, models were composed using the analysis set,
predicting the dispensing of the interacting drug com-
binations. The models were validated using the vali-
dation set. The number of questions was too large
for the multivariate analysis, and only a limited
number of questions were selected. From every
chapter, those questions were selected that correlated
with the other questions and that could discriminate
between pharmacies.
Results
The database contained a total of 100,295,311 dispen-
sings in the selected study period. One thousand one
hundred and forty-two pharmacies were recorded in
the database with 5,000 or more dispensings. The
number of dispensings per pharmacy varied from 5,019
to 264,631. Because pharmacies receive reimburse-
ments from several health care insurance companies
and because not all health care insurance companies
were included in the database, these numbers do not
correspond with the total number of dispensings per
pharmacy. The eleven potential D–DIs were dispensed
11,594 times. In 5%, more than one pharmacy was
involved. As these D–DIs could not be assigned to a
single pharmacy, they were excluded from further
Table 2 The subjects and number of questions in the questionnaire
Chapter Subject (number of questions)
General pharmacy data Ownership of the pharmacy (1), cooperation with other pharmacies (1), cooperation with general
practitioners (1), electronic submission of prescriptions (4)
Facilities Alterations (2)
Quality policy Setting up and implementing a quality system (4), certiﬁcation (2), attitude towards quality
management (12)
Quality measurement Measurement of errors (2), complaints (1), patient satisfaction (2), interventions (3), and
participation in mystery guest investigations (2)
Receipt procedure Number of personnel involved in dispensing a receipt (2), checks in dispensing a receipt (3)
Medication
surveillance—tuning
software
Medication surveillance system used (1), tuning of the system e.g. which signals are showed and which
are regarded as irrelevant (55
a), surveillance of pharmacy preparations (2)
Medication
surveillance—organisation
The way technicians are instructed to manage medication surveillance signals (5), the way this is
supervised (2), number of interventions (1), use of resources (2), participation in courses (4),
management of the D–DI between carbamazepine and erythromycin (5) and between
Sulfamethoxazole/trimethoprim and Acenocoumarol (7)
Medication surveillance—
recording management
The way the management of signals is recorded (4)
Pharmacy preparations The way instructions for pharmacy preparations are recorded (1), the way pharmacy preparations are
supervised (3), the number of pharmacy preparations (2), the policy regarding analysing pharmacy
preparations (3)
Personnel and workload Subjective workload (3), absence through illness (1), number of receipts dispensed per technician (2),
personnel and experience of personnel (18)
Patient care Information given to patients (6), information exchange with hospitals (4), participation in health
care projects (4)
Farmacotherapeutic
consultation groups
Participation in farmacotherapeutic consultation groups (3), agreements made (3)
a As the questions for the four systems (Pharmacom, Aposys, Euroned, others) differed, pharmacists had to ﬁll in only a quarter of
these questions
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123analyses. The number of dispensings and D–DIs are
shown in Table 1. Disopyramide (D–DI number 6) and
azapropazon (D–DI number 11) were not dispensed
by 44% and 46% of the pharmacies, respectively.
Therefore, a ratio could not be calculated for these
pharmacies and these D–DIs were excluded from the
analyses.
The number of times a ratio above one was found
was calculated (Table 1) and pharmacies were selected
as shown in Fig. 1. Two hundred and sixty-eight
pharmacies were selected to receive a questionnaire
and 74 pharmacies were selected for a visit by the IHC.
For several reasons, such as recent visitations and
duplications in the database, 12 pharmacies were ex-
cluded. Eventually, 256 pharmacies received a ques-
tionnaire and 62 pharmacies were selected for a visit.
Two hundred and forty-six questionnaires were ﬁlled in
(response rate 96.1%) and 58 (93.5%) pharmacies were
visited after the questionnaire was completed. The
judgements during the visits by the IHC were com-
pared with the answers by the pharmacists. In 33 of the
37 veriﬁed questions, the IHCs judgement matched in
more than 90% the answer of the pharmacist. Except
four questions, the judgement by the IHC was equally
more positive and more negative than the answers by
the pharmacist.
In the univariate analysis, all combinations between
the questions and D–DIs were searched for signiﬁcant
correlations. Two correlations were found with D–DI
number 1 between macrolide antibiotics and digoxin
(Table 3). Pharmacies, which are part of a health care
centre dispensed this interacting drug combination
more often than other pharmacies. A correlation with
the type of medication surveillance system was also
found. Pharmacies using the Euroned system dis-
pensed this interacting drug combination more often,
while pharmacies using the Pharmacom system dis-
pensed this interacting drug combination less often.
For the multivariate analysis, 32 variables were se-
lected, representative of the whole range of questions.
These variables were used in the analysis-set to com-
pose models. The adjusted explained variance ranged
from 2.6% to 28.9% (Table 4). The model explaining
the D–DI between macrolide antibiotics and digoxin
had by far the highest adjusted explained variance. The
models were validated in the validation-set, calculating
the unexplained variance (Table 4). The six variables
in this model explaining the D–DI between macrolide
antibiotics and digoxin are shown in Table 5.
Discussion
In this study, we investigated determinants for the
dispensing of 11 undesirable interacting drug combi-
nations. In general, our results are in line with the
expectation that the medication surveillance system
plays an important role in medication surveillance.
Although the 11 potential D–DIs were counted 11,594
times which suggests that a considerable number of
patients is exposed to potential and avoidable adverse
patient outcomes, these results should be judged
against a background of approximately 100 million
dispensings. It is possible that in these cases due to
particular circumstances any other option, such as
substituting or not dispensing one of the drugs, is a less
favourable choice than dispensing the D–DI. In 5% of
the total number of D–DIs more than one pharmacy
was involved, indicating the importance of communi-
cation. For the D–DI between macrolide antibiotics
and digoxin, two determinants were found. Although
the type of medication surveillance system was a
determinant, this does not mean that the differences
are determined by the quality of the system itself be-
cause they may also correlate with the attitude of the
pharmacists using the systems. The three medications
surveillance systems differ in the extent to which
Table 4 Predictabilityofthemodelscomposedinthemultivariate
analysis
D–DI Adjusted explained
variance (R
2) (analysis set)
Unexplained variance
a
(validation set)
1 28.9 0.61
2 12.8 –0.22
3 17.3 31.5
4 7.0 –0.18
5 14.4 –0.41
7 6.5 6.4
8 16.1 0.68
9 14.0 –0.43
10 2.6 0.90
a An unexplained variance of zero means that the predictability
found in the validation set equals the predictability in the anal-
ysis-set. The higher the unexplained variance, the worse the
predictability in the validation-set compared to the analysis-set
Table 3 Signiﬁcant univariate correlations between the ques-
tionnaire and the number of dispensings of the D–DIs between
macrolide antibiotics and digoxin (number 1)
Question Correlation Signiﬁcance
Is the pharmacy part of a health care
centre? (1 yes, 2 no) (yes n = 18, no
n = 228)
–0.165 0.009
Which medication surveillance system is used in the pharmacy?
Pharmacom (1 yes, 0 other) (n = 81) –0.261 0.000
Aposys (1 yes, 0 other) (n = 62) 0.088 0.170
Euroned (1 yes, 0 other) (n = 89) 0.197 0.002
Pharm World Sci (2007) 29:51–57 55
123communication with other healthcare providers is
possible and developments were made in recent years.
The Pharmacom system has the most advanced com-
munication possibilities and compared to the other
systems, new developments to the Euroned system
were modest. Unexpectedly, pharmacies part of a
health care centre dispensed this D–DI more often
than other pharmacies. In health care centres, the
communication lines between pharmacists and general
practitioners are much shorter, suggesting that inter-
vening undesirable D–DIs will be easier. Possibly,
pharmacies which are part of a health care centre op-
pose the opinions from the general practitioners less
often, to avoid harming the cooperation within the
health care centre but, of course, there may be several
other reasons.
For the other eight assessed D–DIs no determinants
were found in the univariate analysis, neither did the
models in the multivariate analysis have a good pre-
dictability. A possible explanation is that the quality of
medication surveillance in community pharmacies in
the Netherlands is high. Therefore, the number of
pharmacies dispensing high-risk D–DIs seems to be
small.
Our study has some potential limitations. First,
because we used strict inclusion criteria to prevent
false-positive results, it is likely that the number of
dispensings of undesirable interacting drug combina-
tions in this study is an underestimation and it is pos-
sible that important determinants were not recognized
or difﬁcult to assess. In the univariate analyses, only
those questions are given which had a signiﬁcant
(p < 0.01) correlation in two independent sets.
Although we included 183 questions and nine D–DIs in
the univariate analysis, the possibility of including a
signiﬁcant correlation by chance was small (on average
0.16 question). Second, the reimbursement data from
eight health care insurance companies were used. In
the Netherlands, these companies work mostly
regionally. It is nevertheless not to be expected that the
determinants of dispensing interacting drugs differ per
region or that pharmacies differ in their management
of D–DIs between patients of different health care
insurance companies. Third, from all potential D–DIs,
only 11 (but highly clinically relevant ones) were
selected for this study. According to the Dutch guide-
lines, for all 11 combinations the dispensing of an
alternative was strongly advised as a good alternative
was available. Nevertheless, it is possible that these
dispensings were not an error because any other option
was not possible. For example, when a patient is
hypersensitive to the alternative drug recommended in
Table 5 The questions in the multivariate model predicting the dispensing of the D–DI between macrolide antibiotics and digoxin
(number 1)
Variable: Answer (coding) Direction
coefﬁcient
Constant 3.3679
Is the pharmacy part of a health care centre? (yes n = 18, no n = 228) Yes (0) versus no (1) –2.2749
Co-trimoxazole—acenocoumarol: no appointments were made with the GPs.
The drug will be dispensed.
Option 1 ‘with all GPs’ (1) versus
other option (0) (n = 11)
Reference
Eight options of choice option 1 ‘with all GPs’ and option Option 2 (1) versus other option
(0) (n = 10)
1.0308
Eight ‘with no GPs’ Option 3 (1) versus other option
(0) (n =4 )
0.3788
Option 4 (1) versus other option
(0) (n =4 )
–0.4542
Option 5 (1) versus other option
(0) (n =3 )
0.9026
Option 6 (1) versus other option
(0) (n =2 )
–0.5100
Option 7 (1) versus other option
(0) (n =4 )
–0.1912
Option 8 ‘with no GPs’ (1) versus
other option (1) (n = 202)
0.0886
Are separate signal texts in the medication surveillance program adjusted to the
situation in the pharmacy? (yes n = 72, no n = 165)
Yes (0) versus no (1) 0.1793
Is the management of signals traceably recorded on the receipt? (yes n = 211, no
n = 35)
Yes (0) on the receipt, no not
on the receipt (1)
0.2691
The supervision on management of signals takes place on the basis of signal lists
(yes n = 158, no n = 86)
Yes (0) on the basis of signal lists,
no (1) not on the basis of signal
lists
0.0723
How many receipts are dispensed per year divided by the number of fte technicians <10
–4
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123the guidelines or when the alternative drug is not
effective. In these cases, the beneﬁt of both drug
therapies should be weighed against the potential risks
of the D–DI. The potential risks can partly be avoided
by taking appropriate measures such as monitoring of
drug levels. In this study, we could not retrieve why the
pharmacist had dispensed the interacting drug combi-
nation, and whether the dispensing was erroneous or
not.
Fourth, the questionnaire was composed on the
basis of a literature search and interviews with experts.
It is possible that not all characteristics correlating with
the dispensing of undesirable interacting drug combi-
nations were disclosed, such as differences in popula-
tion characteristics between pharmacies. For example,
pharmacies with an elderly population using more
drugs simultaneously have a higher risk of dispensing
interacting drug combinations than pharmacies with a
younger population. Also, it is possible that in areas
with many general practitioners who use a medication
surveillance system for prescribing, the background
chance of a D–DI is much smaller. Fifth, it is possible
that the differences between pharmacies were too
small compared with the power of this study to dis-
tinguish determinants.
All associations found in this study were directly
related to the management of signals. In our ques-
tionnaire, we also included other topics, such as phar-
macy preparations and patient care. Future research
should focus on the management of a larger variety of
signals than the ones in our study and on how D–DI
associated dispensing could be further reduced.
Conclusion
In conclusion, both medication surveillance systems
and being part of a health care centre may play an
important role in the management of D–DIs and the
avoidance of adverse patient outcomes. Pharmacies in
a healthcare centre dispensed D–DIs more often. For
most D–DIs, no determinants were found possibly
indicating that the quality of medication surveillance in
the Netherlands is high.
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